1. Acute Management of Bell’s Palsy
- Author
-
K. Geißler, G. F. Volk, T. Granitzka, J. Thielker, O. Guntinas-Lichius, and Carsten M. Klingner
- Subjects
medicine.medical_specialty ,Standard of care ,Palsy ,business.industry ,Outcome measures ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Otorhinolaryngology ,Bell's palsy ,medicine ,Prednisolone ,Immunology and Allergy ,Surgery ,Neurology (clinical) ,Acute management ,030223 otorhinolaryngology ,Intensive care medicine ,business ,Psychosocial ,030217 neurology & neurosurgery ,medicine.drug - Abstract
To report the standard of care, latest advances, interesting new findings, and controversies about the treatment of Bell’s palsy in the acute phase. Treatment with prednisolone alone within 72 h still is the treatment standard. The role of antivirals still is unclear. Since 2009, no trials with influence on the treatment standards have been performed. A study to clarify the role of prednisolone treatment in children is ongoing. Patient-related outcome measures like the Facial Clinimetric Evaluation Scale and the Facial Disability Index are important tools to assess the quality of life and psychosocial impact of Bell’s palsy next to the motor deficits. Simplified subjective electronic grading systems like the eFACE and first automated image analysis systems have been introduced. Studies clarifying the role of antivirals for severe cases are urgently needed as well as an international consensus on the outcome measures in diagnostics and follow-up.
- Published
- 2018
- Full Text
- View/download PDF